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Available online 21 March 2019Background: Genome-scale metabolic models (GEMs) offer insights into cancer metabolism and have been used
to identify potential biomarkers and drug targets. Drug repositioning is a time- and cost-effectivemethod of drug
discovery that can be applied together with GEMs for effective cancer treatment.
Methods: In this study, we reconstruct a prostate cancer (PRAD)-speciﬁc GEM for exploring prostate cancer me-
tabolism and also repurposing new therapeutic agents that can be used in development of effective cancer treat-
ment. We integrate global gene expression proﬁling of cell lines with N1000 different drugs through the use of
prostate cancer GEM and predict possible drug-gene interactions.
Findings:We identify the key reactionswith altered ﬂuxes based on the gene expression changes and predict the
potential drug effect in prostate cancer treatment. We ﬁnd that sulfamethoxypyridazine, azlocillin,
hydroﬂumethiazide, and ifenprodil can be repurposed for the treatment of prostate cancer based on an in silico
cell viability assay. Finally, we validate the effect of ifenprodil using an in vitro cell assay and show its inhibitory
effect on a prostate cancer cell line.
Interpretation: Our approach demonstate how GEMs can be used to predict therapeutic agents for cancer treat-
ment based on drug repositioning. Besides, it paved a way and shed a light on the applicability of computational
models to real-world biomedical or pharmaceutical problems.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Genome-scale metabolic models
Drug repositioning
Drug repurposing
Prostate cancer
Approved drugs1. Introduction
Prostate cancer (PRAD) is one of themost prevalent cancers without
the distinction of gender and it is the second-most prevalent cancer
among men, according to the latest worldwide cancer statistics [1]. Re-
cently, PRAD has been reported in the United States as the ﬁrst most
common cancer type in estimated new cases and the secondmost com-
mon cancer type leading to deaths after lung and bronchus cancer in
men [2].
Genome-scale metabolic models (GEMs) have been used to study
cancer metabolism using either generic/personalized or tumor/cell-
speciﬁc types,whichmight translate into clinically relevant applications
[3,4]. These tools can also be used to identify drug targets leading torga), adilm@scilifelab.se
. This is an open access article underinhibition of cancer-related phenotypes or prediction of drug resistance
in cancer therapy [5,6].
GEMs can be used as powerful tools to stratify the patients or deter-
mine pivotalmediator genes in cancermetabolism, intertwining biolog-
ical pathways, and metabolites that supply energetic and biosynthetic
demands in cancer cells [7,8]. Additionally, GEMs can be applied to iden-
tify novel targets and drugs and to create and/or test the hypotheses in
the context of drug discovery or drug repositioning [9,10]. The predic-
tion power of GEMs in determination of adverse drug effects and critical
metabolic reactions usingmachine learning approaches was also inves-
tigated [11]. Emphasis on organ- or tissue-speciﬁc constraint-based
models might be a crucial facet in obtainingmore accurate and relevant
drug effect or side effect predictions for the target tissue [12,13]. In de-
scribing the metabolic organization consisting of different components
such as enzymes, metabolites, etc., GEMs offer the opportunity for dy-
namic assessment of metabolism to investigate drug action and even
side effects using various computational modeling methods [14]. Since
the metabolic alterations have the utmost importance in diagnosis orthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
Genome-scale metabolic models (GEMs) have been used to study
metabolism in clinically relevant applications such as stratifying
the patients, determining pivotal mediator genes or biological
pathways in disease state and discovery of potential biomarkers
and drug targets. GEMs also offer the opportunity for prediction
of relevant drug effect or side effect for a target cell or tissue.
Added value of this study
In this study, we first reconstructed PRAD-specific GEM by inte-
grating tissue-specific proteomics and transcriptomics data.
After interpretation of drug-induced transcriptomics data through
ConnectivityMap2, we predicted novel gene-drug interactions to
reveal drug off-targets. To the best of our knowledge, this study
is the first GEM application that used drug repositioning and in
silico cell viability assay, simultaneously. We also performed
in vitro cell viability assay to show inhibitory effect of ifenprodil
as a novel drug candidate for prostate cancer treatment.
Implications of all the available evidence
We demonstrated that GEMs can be used as promising tools for
real-world biomedical and pharmaceutical applications. Organ- or
tissue-specific constraint-based models might be a crucial facet
to determine drug effects in treatment of different diseases. Not
only approved drugs, abandoned or withdrawn drugs might be
used in this application for novel drug repositioning candidates
for different diseases.
387B. Turanli et al. / EBioMedicine 42 (2019) 386–396treatment of PRAD, regardless of disease stage [15], GEMs are also pow-
erful tools for PRAD studies as well.
In this study, we reconstructed a disease-speciﬁc GEM for PRAD by
combining personalized GEMs (n N 450) and prostate cancer-speciﬁc
proteomics data. Subsequently, the representative potential of the met-
abolic model for the disease phenotype was evaluated through essenti-
ality analysis applied to the metabolic model and evaluation of
transcriptome data to explore tightly connected pathways via differen-
tial rank conservation (DIRAC) [16] analysis. After interpretation of the
metabolic phenotype of the disease, we determined the metabolic
gene signatures for drug repositioning. Gene expression data from
drug-perturbed cancer cell lines was acquired from ConnectivityMap2
(CMap2) [17] and recapitulated to reveal candidate drugs thatmight re-
versemetabolic gene expressions and predict gene-drug interactions. In
addition, drug action simulations were performed via reconstructed
PRAD-speciﬁc GEM and resulted in four drugs repurposed for the treat-
ment of prostate cancer based on in silico cell viability assays. We vali-
dated one of the candidate drugs in vitro and showed that ifenprodil is
a promising candidate that has an inhibitory effect on the PC3 cancer
cell line (Fig. 1).2. Results
2.1. Reconstructed PRAD-speciﬁc GEM comprises individual transcriptome
and tissue-speciﬁc proteome data
Signiﬁcant heterogeneity among prostate tumors might hinder
characterization of PRAD and its biological pathways compared with
the noncancerous prostate. Therefore, we reconstructed a consensus
PRAD-speciﬁc GEM based on N450 personalized PRAD GEMs thatcontains all metabolic reactions and respective gene expressions in
prostate cancer patients.
After following the existingRNA-seq data analysis protocol [8], PRAD
tissue proteome from the Human Protein Atlas (HPA) [18] was used to
make the model more representative and robust. The expression pro-
ﬁles for 14,778 protein-encoding genes were obtained either at the
transcriptome and/or proteome levels. In addition, the expressions of
8558 (57.9% of all protein-coding genes) genes were detected in PRAD
at both the transcriptome and proteome levels (Fig. 2A). A total of
3328 proteome-based and 2892 transcriptome-based signatures were
also included in the model reconstruction practice as input (Fig. 2A).
As a result, the PRAD-speciﬁc GEM consists of 2655 genes and 6718 re-
actions, which represent individual variations in PRADmetabolism. The
majority of the genes in the reconstructed model was incorporated in
both proteomic and transcriptomic data (Fig. 2B). iCancerCore [18] is
designed as a generic cancer metabolism model, and a PRAD-speciﬁc
GEM was reconstructed based on this generic model. The generic and
PRAD-speciﬁc models share common signatures for 2655 genes and
6718 reactions (Fig. 2C–D). However, the personalized PRAD GEMs re-
trieved from the Human Pathology Atlas have different numbers of
genes (978–2031) and reactions (2179–5053). The PRAD-speciﬁc
GEM covers all genes and reactions represented in personalizedmodels,
but each personalizedmodel might represent 37 to 77% of genes and 33
to 76% of reactions in the PRAD-speciﬁc GEM (Fig. 2E–F). These results
recapitulated the cancer heterogeneity, as previously shown [18].
2.2. Network-based independent analyses of PRADmetabolism consistently
highlight altered lipid metabolism/steroid biosynthesis pathways
To reveal the global biological differences between PRAD tumors and
nontumor prostate tissue, we ﬁrst identiﬁed differentially expressed
genes (DEGs) using differential expression sequencing (DESeq) and
found a total of 3776 DEGs (adj. p-value b 0.001), of which 2266 genes
were downregulated and 1510 genes were upregulated (Table S1).
To reveal the alterations in metabolism, we also identiﬁed reporter
metabolites using the network topology supplied by the reconstructed
PRAD-speciﬁc GEM. The reporter metabolites algorithmwas developed
to detect the hotspot of metabolism associated with up- or downregu-
lated genes between two phenotypes [19]. Simulations resulted in 86
upregulated metabolites and 76 downregulated metabolites regardless
of their cellular compartments (Table S2). As an example of upregulated
reporter metabolites, folate moderates the invasiveness of PRAD cells
[20], and elevated physiological levels of folic acid stimulate both
growth and invasiveness of various prostate cancer cell lines [21] in par-
allel with our results. Another upregulated metabolite, prostaglandin
E2, is a bioactive lipid produced from arachidonic acid by cyclooxygen-
ase enzymes (e.g., COX2) and has a positive correlation with prostate
tumor growth and angiogenesis [22]. Moreover, other reporter
metabolites involved in fatty acid biosynthesis, primary bile acid
biosynthesis, fatty acid elongation in mitochondria, one carbon pool
affected by folate, and calcium signaling pathways were associated
with upregulated genes in PRAD. Notably, reporter metabolites such
as 4-alpha-methylzymosterol, 14-demethyllanosterol, 4-alpha-
methylzymosterol-4-carboxylate and 4,4-dimethyl-5alpha-cholesta-8-
en-3beta-ol participating in steroid biosynthesis were associated with
the downregulated genes in PRAD as well as purine-pyrimidinemetab-
olism, nicotinate and nicotinamide metabolism (Table S2).
In addition to the frequently used analyses (i.e., differential gene ex-
pression analysis and determination of reporter metabolites), we
assessed the reconstructed metabolic model with two network-
associated analysis frameworks to evaluate prostate cancer metabolism
in detail.
First, we performed essentiality analysis (Edwards and Palsson,
2000) inwhichGEMs are used to determine essential genes or reactions
whose knock-out or blocking have disabling effects on a speciﬁc biolog-
ical function [23]. The objective function of themetabolic model was set
Fig. 1. Identiﬁcation of potential therapeutic targets in PRAD using in silicomodeling and drug signatures. We performed two independent analyses for disease phenotype evaluation.
Reconstructed models were applied to explore essential genes for PRAD metabolism. Gene expressions from tumor and nontumor tissues were used to ﬁnd tightly regulated pathways
in prostate tumors through GEMs (blue dashed boxes). We subsequently selected metabolic gene signatures based on the differentially expressed genes in the reconstructed model for
drug repositioning. Drugs that show reversal of gene expression for tumor vs. nontumor tissues were identiﬁed together with predicted gene-drug interactions from CMap2. Drugs
with reversal effects and their predicted gene partners were implemented into GEMs as in silico viability tests and further selected for experimental validation due to their in silico
growth-inhibiting effects (green boxes).
388 B. Turanli et al. / EBioMedicine 42 (2019) 386–396to biomass maximization to ﬁnd which genes are essential for tumor
growth. In this study, we determined 23 essential genes (Table S3) by
implementing logic transformation of the model and the FastGeneSL
function [23] with the reconstructed PRAD-speciﬁcmodel. These essen-
tial genes were predicted as key genes with an inhibitory effect on
tumor growth regardless of differential expression. Functional enrich-
ment analysis (Table S3) performed for essential genes indicates that
most were enriched in the steroid biosynthesis pathway (Fig. 2H), in-
cluding genes associated with zymosterol biosynthesis (FDFT1, SQLE,
LSS, CYP51A1, NSDHL, HSD17B7, DHCR24) and cholesterol production
(DHCR24, DHCR7, SC5D, EBP). MVD, HMGCR, MVK and PMVK are
genes enriched in both terpenoid backbone biosynthesis and in the
mevalonate pathway.
Second, we used theDIRAC algorithm [16],which allows assessment
of the combinatorial interactions for quantiﬁcation of various biological
pathways in a comparative sense at the population level to quantify
conservation differences between networks for two phenotypes, in-
cluding tumor and nontumor samples. The analyses revealed that the
lipid metabolism (andmore speciﬁcally glycosphingolipid biosynthesis,
ether lipid metabolism and steroid biosynthesis) is variably expressed
in PRAD compared with noncancerous prostate tissue. Additionally, ri-
boﬂavin metabolism, pentose phosphate pathway, and thyroid cancer
were emphasized in tumor samples (Fig. 2G).
These observations highlighted the steroid biosynthesis pathway as
a mutual result related to lipid metabolism. This pathway has utmost
importance not only for normal prostate development but also for pros-
tate cancer progression [24]. Consistent results supplied from different
analyses revealed the representative functionality of the reconstructed
metabolic model. Previous studies also showed that a signiﬁcantproportion of these genes leading to cholesterol and steroid biosynthe-
sis were abundant in the peripheral zone of prostate tumors, where
prostate tumors primarily arise [25,26]. In addition to consistency of
the inter- and intra- studies of PRAD metabolism, these key genes and
their associated pathways offer an opportunity for drug discovery or
drug repositioning. For instance, lipid-lowering drugs such as statins
showed a beneﬁcial effect in reducing PRAD-related mortality as well
as overall PRAD risk [14].2.3. Elucidation ofmetabolic gene signatures to discover drugswith reversal
expression effect
Metabolic gene signatures were common gene signatures if consid-
ering the intersection of genes in the reconstructed GEM and DEG list,
and this group consists of 274 up- and 367 downregulated metabolic
genes.
Investigation of these genes in the KEGG pathways shows that they
tend to be enriched (p-value b 0.05) in lipid-speciﬁc pathways (e.g.,
sphingolipid, ether lipid, glycerophospholipid, and glycerolipidmetabo-
lism) and in biosynthesis of antibiotics and peroxisome, similar to the
observations elicited by DIRAC and the essentially analysis above. In ad-
dition, these genes are also involved in other pathways such as glutathi-
one, β-alanine, purinemetabolism, arginine-prolinemetabolism,mucin
type O-glycan biosynthesis and drug metabolism-cytochrome P450
(Table S4). These results indicate that despite representing a subset of
all protein-coding genes, the metabolic genes found in the PRAD GEM
are still able to capture the disease metabolism and keymetabolic path-
ways for therapeutic targeting.
Fig. 2. In silicomodeling highlights steroid biosynthesis as a key pathway in PRAD. A. Number of protein-coding genes attained from transcriptomics data via TCGA (blue), and proteomics
data from HPA (green), which were integrated during model reconstruction. Genes were excluded when not detected at the protein level or with FPKM b 1. B. Metabolic genes with
evidence at the protein or transcriptomic levels and connectivity genes required to achieve metabolic feasibility (see Methods). C and D. Number of genes (C) and reactions (D) in
PRAD-speciﬁc GEM and iCancerCore model. E and F. Coverage of PRAD-speciﬁc GEM in terms of gene (E) and reaction (F) numbers. G. Pathway-level fold changes (FC) after DIRAC
analysis (tumors vs. nontumor models) and DAVID functional enrichment analysis for essential genes (p-value b 0.05). H. KEGG steroid biosynthesis pathway highlighting that 11 out
of 23 essential genes (red) are found.
389B. Turanli et al. / EBioMedicine 42 (2019) 386–396The metabolic gene signatures were used as input to query CMap2
for elucidating the differences and similarities between drug-induced
expression proﬁles and disease expression. We queried the CMap data-
base and identiﬁed drugs that showed correlated action mechanisms
with the metabolic gene signatures in either direction. However, we
considered the drugs with negative similarity scores because these
drugs show reversal effects on gene expression in PRAD. As a result,
we identiﬁed 81 signiﬁcantly associated drugs (permutated p-value b0.05), ofwhich 43 drugs present as drug candidateswith reversal effects
of metabolic gene signatures (Table S5).
2.4. Identiﬁcation of potential repositioning drugs for PRAD treatment
based on perturbagen analysis
Seeking to further ﬁlter the predicted drugs and determine drug-
gene interactions as well as the drug effects on gene expression, we
390 B. Turanli et al. / EBioMedicine 42 (2019) 386–396used the drug-perturbed gene expression data of three cell lines (PC3,
HL60, and MCF7). After data harmonization and processing (see
Methods), we determined the Log2 fold changes (Log2FC) in response
to drugs for approximately 12,300 genes in 683 drugs in three cell
lines (Fig. 3A). We used the 3 cell lines since we were seeking to have
a more robust response to the drugs, thus decreasing the potential
false positives that would stem from using only one cell line - i.e.
genes that would show a consistent response to the same drug, regard-
less of embryonic cell origin. Thus, genes whose Log2FC in response to
the same drug differed in 2 cell lines were discarded. Because similar
gene responses to drugs may nevertheless occur, we further combined
the data from each cell line to calculate the conﬁdence scores (CS) for
each drug-gene interacting pair (Fig. 3B). As a proof of concept, a previ-
ous study showed that over 70% of drug-induced gene expressionswere
mutual for multiple cell lines [63]. Although the direction of the expres-
sions was similar, the calculated CS values approximating 1 were not
abundant. The number of geneswith CS N0.5 for each drugwas between
24 and 97 out of 12,228. Mapping of metabolic signatures on the drug-
genematrix containing the conﬁdence score yielded an interaction ma-
trix of 515 genes with 683 drugs (Fig. 3C; Table S6). After processing
(see Methods), we selected gene-drug interactions with CS N 0.5 as
those capable of altering the reaction ﬂuxes in the metabolic model.
Drug targets of the purposed interactions in this study share a simi-
lar protein family with known anti-cancer drug targets such as solute
carrier (SLC) transporters, growth factors or enzymes such as carbonic
anhydrases and glutathione S-transferases.
SLCs are transporter membrane proteins that are primarily involved
in the uptake of the drug and thus might inﬂuence chemotherapy efﬁ-
cacy and/or toxicity. The members of the SLC protein family showed
substantially different expression proﬁles in cancer cells compared
with healthy cells, and in this manner, they are discussed as potential
drug targets in cancer therapy [27]. Among all identiﬁed targets (CS NFig. 3. Integration of computationally predicted potential therapeutic targets and drug-gene asso
of PRAD. A. Heatmaps showing gene expression responses to drugs (Log2FC) generated for 3 cel
resulted in 683 drugs found in the 3 cell lines after quality control. Only genes with mean ab
association in each cell line. Z-scores were computed, and the p-values were integrated by the n
metabolic effect and 515 of metabolic gene signatures.0.5), 10% are from SLC protein family. For instance, SLC19A1 is one of
the major facilitative folate and thiamine transporters [28] and is a pre-
dicted target of norcyclobenzaprine (Fig. 4). Carbonic anhydrases (CAs,
EC 4.2.1.1), another predicted drug target group, were previously used
to treat several diseases such as glaucoma, obesity, infections, and can-
cer and especially applied to overcome chemoresistance [29]. To the
best of our knowledge, carbonic anhydrase CA1 has been mentioned
as a potential plasma biomarker in prostate cancer diagnosis [30] but
not as a drug target for treatment. This study proposed that CA12 inter-
acts with ifenprodil. Fibroblast growth factor receptor (FGFR) was asso-
ciated with azlocillin, sulfamethoxypyridazine, chloramphenicol, and
dexpropranolol in the study (Fig. 4). FGFR is one of the studied drug tar-
gets for multiple cancer types [31]. The involvement of FGF/FGFR path-
ways in prostate cancer and their associations with angiogenesis and
disease progression offer a rationale for FGFR as potential therapeutic
target. FGF/FGFR pathways targeting dovitinib and nintedanib are two
small-molecule tyrosine kinase inhibitors in clinical development for
advanced prostate cancer [32]. Glutathione S-transferases (GSTs, EC
2.5.1.18) are represented by GSTM3, GSTM4, GSTZ1 and MGST3 in
drug targets (Table S7). Different GSTs polymorphisms and overexpres-
sion have already been identiﬁed as potential biomarkers in different
cancers, including fatal prostate cancer [33]. Recently, GSTM3 polymor-
phism has been observed in prostate cancer patients and associated
with resistance to hormonal therapy through oxidative stress [34]. Ge-
netic polymorphisms of GSTs and their functional reﬂections in cancer
patients were correlated with chemotherapeutic efﬁcacy. Therefore,
GSTs have gained importance as candidate targets for design of speciﬁc
drugs to solve the drug resistance problem [35,36]. Because the overex-
pression of GSTs and efﬂux pumps cause increased discharge of anti-
neoplastic drugs, the use of GST inhibitors such as ethacraplatin,
ethacrynic acid and analogs, auranoﬁn or piperlongumine might ad-
dress drug resistance and increase anti-cancer drug sensitivity in cancerciation proﬁles that induce reversal ofmetabolic signatures predict 23 drugs for treatment
l lines (PC3, HL60,MCF7) to identify common drug responses across cell lines. This analysis
solute log2FC N 0.2 are shown. B. Conﬁdence scores were calculated for each drug-gene
aïve Bayesian formula. C. Conﬁdence scores for interactions among 23 drugs with reversal
Fig. 4. Candidate drugs and their interacting genes that induce reversal effects in PRAD expression. A. Direction of 515 gene expressions induced by 23 drugs and drug-associated KS
similarity score and p-value after random permutation testing. A total of 11 of candidate drugs, which have not been previously associated with PRAD cases, are highlighted
(turquoise). B. Drug-gene association network composed of 11 candidate drugs and 71 genes with CS N0.5 and reversal expression patterns. Genes are highlighted if their expression is
upregulated by the drug but downregulated in disease (purple) or vice versa (light blue). Edge represents conﬁdence scores from 0.5 to 1. Several drugs (ifenprodil, azlocillin,
sulfamethoxypyridazine, hydroﬂumethiazide, morantel) show inhibitory effect after in silico cell viability testing (diamonds).
391B. Turanli et al. / EBioMedicine 42 (2019) 386–396cells. Another opportunity for cancer therapy is the use of prodrugs such
as canfosfamide, nitric oxide prodrugs, metformin and doxorubicin an-
alogs [37].2.5. In silico cell viability test for each drug through GEMs
To test the drugs with reprogramming of PRAD metabolism back to
nontumor phenotype, we sought to identify drugs that could reverse
the expression effects in tumor vs. nontumor tissues as well as their
drug-interacting gene partners. An examination of 683 drugs from the
drug-gene interaction matrix and 43 drugs that show signiﬁcant rever-
sal of gene expression effects based on themodiﬁed KS-test and random
permutations resulted in 23 drugs (Table S5; Table 1). We manually
reviewed these candidate drugs on PubMed to ﬁnd the association of
drugs with prostate cancer. The literature review showed that 12 of 23
drugs have been already associated or tested for treatment of PRAD, fur-
ther reinforcing our conﬁdence in our observations. We considered
these results as positive controls for the following analyses. The remain-
ing 11 drugs have not been previously identiﬁed as anti-cancer agents.
Among these 11, various drug groups were identiﬁed, including anti-
bacterial, anti-helminthic and anti-protozoal agents, diuretics, opioids,
β-adrenergic antagonist and NMDA receptor inhibitor types. For further
investigation, we focused on 94 interactions among 11 PRAD non-
associated drugs and 71 genes with reverse directionality of expression
(Fig. 4).
Drug targets (CS N 0.5) for these 11 drugs were enriched in KEGG
pathways such as biosynthesis of antibiotics, biosynthesis of amino
acids, glyoxylate and dicarboxylatemetabolism, and central carbonme-
tabolism in cancer, whereas O-glycan processing, protein glycosylation,
long-chain fatty acid metabolism, sterol and cholesterol biosynthesis,
lipid metabolism, glutathione-derivative biosynthesis, dephosphoryla-
tion, folic acid metabolism and transport were biological processes
(Table S8).The full list of 23 PRAD-associated drugs were analyzed through the
PRAD-speciﬁc GEM, and eight of the 12 PRAD-associated drugs showed
an inhibitory effect (a decrease in biomass production rate N1 × 10−8)
for tumor growth through themetabolicmodel regardless of the thresh-
old for drug effect between 15%–25% (Table 1). The missing PRAD-
associated drugs, meptazinol, thiostrepton, metyrapone and
ursodeoxycholic acid, were investigated in reference articles from the
literature review. Metyrapone is applied for the temporary control of
Cushing's syndrome as a paraneoplastic manifestation of prostate can-
cer in a patient and was found to be effective, with few side effects
[38]. Thiostrepton decreases viability of various prostate cancer cell
lines, but its apoptotic effectiveness increases in combination therapy
with anticancer agents ABT-737 and bortezomib for treatment of
PRAD [39]. Ursodeoxycholic acid showed no signiﬁcant effects on
growth of prostate cancer cells, whereas synthetic derivatives of the
drug completely inhibited cell proliferation [40]. The opioid analgesic
meptazinol has been mentioned as a signiﬁcant computational predic-
tion based on PRAD transcriptome dataset results queried on CMap2
[41]. To the best of our knowledge, no experimental validation exists
for meptazinol against prostate cancer. Moreover, other PRAD-
associated drugs showed in silico inhibitory effects on PRAD growth in
parallel with previous studies (Table 1).
After the in silico cell viability test through PRAD-speciﬁc GEM in this
study, 4 in 11 drugs were highlighted as novel candidates:
sulfamethoxypyridazine, azlocillin, morantel, and ifenprodil. Later, we
also checked the drug effects for 90% and 80% inhibition of tumor
growth (Table S9). After sensitivity analysis composed of different
growth-inhibition effects, another drug known as hydroﬂumethiazide
also showed an effect on PRAD biomass. Furthermore, we simulated
the effect of these on healthy prostate tissue to predict their lethal ef-
fects for each biological task (Table S10). Then, we evaluated results
(Table S11) for our candidate drugs which were expected to inhibit
tumor growth, while not being excessively lethal to healthy prostate
cells.
Table 1
In silico cell viability test results of 23 drugs whichwere predicted to reverse gene expression in prostate cancer regarding KS similarity score and permutation-based p-value from CMap2.
Drugs Permutation-based p-value Similarity Score References In silico
Cell viability
Thiostrepton 0.001 −0.488 [39] ✖
Geldanamycin 0.001 −0.283 [64] ✔
Pentamidine 0.008 −0.383 [65] ✔
Triﬂuoperazine 0.014 −0.317 [66] ✔
Tanespimycin 0.000 −0.281 [66] ✔
Meptazinol 0.041 −0.377 [41] ✖
Alvespimycin 0.008 −0.280 [67] ✔
Suloctidil 0.031 −0.324 US 2006/0009506A1 ✔
Pyrvinium 0.018 −0.362 [68] ✔
Metyrapone 0.040 −0.338 [38] ✖
Tyloxapol 0.041 −0.409 [69] ✔
Ursodeoxycholic acid 0.018 −0.463 [40] ✖
Hydroﬂumethiazide 0.003 −0.408 – ✔
Dexpropranolol 0.007 −0.489 – ✖
Norcyclobenzaprine 0.035 −0.417 – ✖
Glafenine 0.046 −0.239 – ✖
Sulfamethoxypyridazine 0.004 −0.430 – ✔
Cetirizine 0.012 −0.493 – ✖
Azlocillin 0.008 −0.440 – ✔
Morantel 0.038 −0.361 – ✔
Chloramphenicol 0.017 −0.426 – ✖
Pentoxyverine 0.034 −0.412 – ✖
Ifenprodil 0.019 −0.353 – ✔
392 B. Turanli et al. / EBioMedicine 42 (2019) 386–3962.6. Ifenprodil as a repositioned drug candidate inhibits prostate cancer
metabolism
We used a CCK-8 assay to assess the effect of ifenprodil on the cell
viability of the human prostate epithelial cell line (RWPE-1), and pros-
tate cancer cell lines (LNCap, 22Rv1, PC3). All cell lines were treated
with 100 μM concentration of ifenprodil. We determined cell viability
after two days and four days and compared the inhibitory effect of
ifenprodil between prostate epithelial cell line and cancer cell lines.
The results showed that ifenprodil treatment with 100 μM concentra-
tions signiﬁcantly reduced three cancer cell lines viability time depen-
dently (Fig. 5). Interestingly, 100 μM concentration of ifenprodil
treatment did not reduced RWPE-1 cell viability but all prostateFig. 5. Experimental detection of the inhibitory effect of ifenprodil on the proliferation of the pro
and three prostate cancer cell lines were exposed to100μM of ifenprodil, and cell viability wa
computed from the hexaduplicate experiments. * p-value b 10−5.cancer cell lines (LNCap, 22 Rv1, and PC3). It showed statistical signif-
icantly reduced cell viability. In previous studies, ifenprodil showed an
inhibitory effect on human esophageal cancer cell lines via NMDA
receptor-mediated apoptosis [42]. There are also previous studies
that NMDA receptor antagonists including ifenprodil have been tested
in vitro and in vivo for ovarian cancer [43] and pancreatic cancer [44].
Ifenprodil has been reported more effective compared to other NMDA
inhibitors within the well below doses known to have signiﬁcant be-
havioral effects in rodents [44]. Treatment concentrations of ifenprodil
were up to 800 μM for pancreatic cell lines (PanC-1, BXCPC3, HPAC)
and ovarian cell lines (A2008, A2780, SKOV3) whereas the half-
maximal inhibitory concentration of the drug was approximately
400 μM [43,44].state ﬁbroblast and prostate cancer cell lines. RWPE-1 human prostate epithelialﬁbroblast,
s tested after 2 and 4 days. Boxes show mean and standard deviation for cell viability as
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GEMs have been used to study cancer metabolism using either ge-
neric/personalized or tumor/cell-speciﬁc types, which might translate
into clinically relevant applications. These tools can also be used to iden-
tify drug targets leading to inhibition of cancer-related phenotypes or
drug resistance in cancer therapy [5]. The prediction power of GEMs
in determination of adverse drug effects and critical metabolic reactions
using machine learning approaches was also investigated [11]. Empha-
sis on organ- or tissue-speciﬁc constraint-based models might be a cru-
cial facet in obtaining more accurate and relevant drug effect or side
effect predictions for the target tissue [12,13]. In this sense, we ﬁrst re-
constructed PRAD-speciﬁc GEM reinforced by tissue-speciﬁc proteome
and individual transcriptome data and compared with previous PRAD
GEM [45].
Our identiﬁcation of altered lipidmetabolism in PRADGEMhas reca-
pitulated the fact that reprogramming of the lipid metabolism plays an
important role in lipid signaling andmeeting the energy demand for in-
creased cell proliferation, macromolecule use in membrane synthesis
and cell growth during tumorigenesis and tumor progression [26,46].
Increasing evidence exists for metabolic reprogramming in lipid path-
ways of different cancer types [47,48], including prostate cancer cells
[49]. Key gene regulators of PRAD lipid metabolism such as fatty acid
synthase (FASN) and alpha-methylacyl-CoA racemase (α- AMACR)
were differentially expressed in this study, in parallel with the ﬁndings
of previous studies [50,51].
To the best of our knowledge, no previous effort to repurpose a drug
through PRAD-speciﬁc GEM has been reported. A recently published
drug repositioning study for PRAD treatment via GEMs applied on two
clonal subpopulations from a PC-3 cell line was used to uncover poten-
tial subpopulation-speciﬁc drug targets. Etomoxir, an inhibitor of long-
chain fatty acid transport to the mitochondria, has been repurposed to
treat PRAD subpopulations that have a similar phenotype of highlymet-
astatic and low invasive type PC3 cells [52].
In parallel to increasing interest in drug off targets, prediction of
gene-drug interactions becomes a challenging task that must be
achieved using different approaches, including text mining, drug-
induced gene expressions, drug binding sites, drug side effects, and
therapeutic effects (Cheng et al., 2017). In this study, we used drug-
induced gene expression proﬁles to test the drugs via GEM. However,
other methods such as comparison of chemical structures and the moi-
eties of repurposed drugs might also be emphasized. For instance, the
moiety of sulfamethoxypyridazine is also present in other medications,
including thiazide diuretics such as hydroﬂumethiazide repurposed in
this study or sulfonylureas (e.g., glipizide) and certain COX-2 inhibitors
(e.g., celecoxib) that are already repurposed for prostate cancer treat-
ment [14]. Not only limited to structural similarities, drugs with similar
functions such as anti-bacterial agents (e.g., clofoctol, nitroxoline) are
also repurposed for prostate cancer treatment [14], including the
azlocillin and sulfamethoxypyridazine drugs repurposed in this study.
Four candidate drugs elucidated after in silico cell viability test were
discussed detailed (Text S1). Since ifenprodil has been tested in vitro in
addition to in silico cell viability analysis, the potential use of NMDA re-
ceptor inhibitors in cancer treatment is investigated. Inappropriate ex-
pression of NMDA receptors on different cancer cell lines has been
discussed and represented as a potential drug target to control dysreg-
ulated growth, division and invasiveness by regulation of mTOR signal-
ing activity [53]. Moreover, blockade of NMDA receptor activity in
cancer cells not only impairs phosphorylated activation of proteins in
growth cascades but also prolongs survival in metastatic cancers [54].
To the best of our knowledge, Abdul andHoosein [55] supplied evidence
for NMDA receptor expression and activity in human prostate cancer
and ten human cancer cell lines, including four prostate cancer cell
lines that were inhibited bymemantine as a NMDA-receptor antagonist
at doses between 5 and 50 μg/ml (23 and 230 μM).We also repurposed
the NMDA-receptor antagonist ifenprodil for treatment of PRAD butthrough predicted off-targets instead of targeting NMDA receptors
directly.
4. Materials and methods
4.1. Genome-scale metabolic model reconstruction for PRAD
Transcriptome data from 495 individuals, composed of 495 primary
prostate tumor and 52 matched nontumor tissues, were acquired from
the NCBI Genome Data Commons [56] using the R/Bioconductor pack-
age “TCGAbiolinks” [57]. Expression data were converted to fragments
per kilobase of transcript permillionmapped reads (FPKM) and ﬁltered
using the criterion ofmedian expression value ≥1 FPKM [8]. To integrate
disease- and tissue-speciﬁc protein information into theGEM, proteome
data were obtained fromHPA version 18.0 [58]. Expression of each pro-
tein was integrated with transcriptome data via abundance levels such
as low, medium and high for use as an input. The iCancerCore model
[18] was selected as a template model for reconstruction via the tINIT
(integrative network inference for tissues) algorithm [59] and the
Mosek solver (version 8) in the RAVEN Toolbox [60]. A total of 471 per-
sonalized GEMs for PRAD were retrieved from the Human Pathology
Atlas [18] and uniﬁed for covering individual metabolic variations in
MATLAB (R2017b). Integration of proteome data into a uniﬁed model
yielded a PRAD-speciﬁc GEM that captures individual metabolic varia-
tions. The biological tasks representing metabolic functions that oc-
curred in all cell types (Table S10) were used to test the functionality
of the metabolic model.
4.2. Differential expressed genes and deﬁning metabolic signatures
Raw count data were used to detect differentially expressed genes
(DEGs) between two phenotypes using the R/Bioconductor package
“DESeq” manual [61]. Multiple hypothesis correction was conducted
using the Benjamini and Hochberg false discovery rate, and those con-
sidered statistically signiﬁcant were used as a multiple correlation test
to calculate q-values. DEGs were ﬁltered based on the threshold of the
FDR adjusted p-value b 0.001. Fold-change cutoff of 1was applied to de-
termine up- and down- regulated genes (Table S1).
PRAD-speciﬁc GEMs comprise 2655 genes, and an intersection of
these genes and DEGs were assigned as “metabolic gene signatures”
for PRAD in this study (Table S4). This set is composed of 641 genes, in-
cluding 274 up- and 367 downregulated genes.
4.3. Reporter metabolites
To identify signiﬁcantly enriched metabolites based on association
with gene expression changes, we recruited the reporter metabolite al-
gorithm embedded RAVEN Toolbox [60], which uses DEGs information
through the network topology of the reconstructed model. These me-
tabolites highlight the central components of the metabolic network
that are affected by perturbations between different conditions [19].
5. Functional enrichment analyses
Functional enrichment analyses were performed in the DAVID func-
tional annotation tool [62] using DEGs as input to identify the enriched
KEGG pathways and GO biological processes.
5.1. DIRAC algorithm
DIRAC [16] was implemented in MATLAB to analyze gene order
within the pathways of the reconstructed model together with other
gene sets. The central concept of the algorithm is based on the relative
expression ranks of the participating genes. The results show a quanti-
tative measurement of how pathway rankings differ both within and
between phenotypes.
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MATLAB incorporated with the RAVEN Toolbox [60] and Mosek
solver (version 8) was applied for GEM operation and analysis of syn-
thetic lethal genes. To determine essential genes, we used logical
transformation of the model and FastGeneSL, as previously described
[23].5.3. Drug repositioning based on reversal of metabolic gene signatures
For robust representation of PRAD metabolism, we identiﬁed the
genes that are differentially expressed inside the reconstructed prostate
cancer metabolic model. DEGs from PRAD GEM were deﬁned as meta-
bolic gene signatures. A total of 641 DEGs, including 274 up- and 367
downregulated genes, were used as a query on Connectivity Map2
(CMap2).
CMap2 consists of 6100 gene expression proﬁles for 1309 drug per-
turbation experiments performed on different cancer cell lines [17]. The
Kolmogorov-Smirnov statistic and random permutation tests are ap-
plied in CMap2 to calculate the similarity scores for a drug-perturbed
expression proﬁle with respect to gene expression proﬁles queried as
input and their statistical signiﬁcance (p-value), respectively. A positive
similarity score denotes the similarity of the drug-perturbed expression
proﬁle to the query, whereas a negative score indicates a reverse pat-
tern. Therefore, the p-value shows the probability of ﬁnding the same
association when a random signature is supplied. Signiﬁcant drugs (p-
value b 0.05) with negative mean values are collected as drug candi-
dates for reversal of metabolic signatures in PRAD.5.4. Interpretation of CMap2 data to repurpose novel gene-drug
interactions
To test the drug efﬁcacy in silico, we aimed to quantify the drug-gene
associations, therefore drug-associated gene expression proﬁles were
included as follows: Connectivity Map (CMap Build 02, https://portals.
broadinstitute.org/cmap/) data from production batches (HT-HG
U133A) was downloaded for 3 cell lines: HL60 (Human promyelocytic
leukemia), MCF7 (Human breast adenocarcinoma), and PC3 (Human
prostate cancer). All analyses were performed individually for each
cell line. Raw data were processed in R using the gcrma package
(https://bioconductor.org/packages/release/bioc/html/gcrma.html),
and single drug treatment and control were selected similarly to [63].
Brieﬂy, after normalization, a single treatmentwith the highest concen-
tration was selected based on those treatments whose gene expression
displayed the highest correlations (results not shown). Outliers based
on hierarchical clustering, and mean gene expression was computed
across controls. This approach resulted in 683 treatment instances and
a single control per cell line. For each cell line, gene Log2FC were com-
puted by comparison between treatment instances and its respective
controls.
Afterward, the conﬁdence score was calculated per each drug-gene
interaction using the Log2FC values from three cell lines. Drug-genema-
trix comprising Log2FC of approximately 12,300 genes and 683 drugs
were assessed for each drug and found normally distributed. Standard
z-scores were calculated and converted p-value for each drug-gene
pair in the matrix for three cell lines (n), separately. Then, the naive
Bayesian formula was modiﬁed to calculate a conﬁdence score for
each drug-gene pair based on the integration of the information coming
from each cell line by using following formula:
CS ¼ ðQni¼1ð1−pvalueði))
Since lower p-value ratios were favorable, an approximation of con-
ﬁdence score to 1 was assumed as the higher conﬁdence level.5.5. In silico drug efﬁcacy test by using PRAD speciﬁc GEMs
Before testing drug efﬁcacy in silico, metabolic gene signatures were
mapped to the gene-drug interaction conﬁdence score matrix, and 526
of 641 DEGs were matched. The ﬁnal matrix of drug-gene interacting
pairs with conﬁdence scores was for 515 genes and 683 drugs
(Table S6).
The intersection of signiﬁcant drug candidates with KS similarity
score below zero and 683 drugs interacting genes with calculated conﬁ-
dence scores yielded twenty-three drug candidates to test in silico drug
effect through the metabolic model. Interacting gene partners of each
drug were extracted regarding the criteria of conﬁdence score N 0.5
and the reversal drug effect of metabolic gene signatures (Table S7).
First, biomass production was set as an objective function to test
drug effect on prostate tumormetabolicmodel. Reactionswhich include
drug interacting genes were assigned as up-reactions and down-
reactions regarding drug perturbed gene expression proﬁles. We esti-
mated the upper and lower bounds for these up- and down-reactions
by random sampling 1000 times. The estimated lower and upper
bounds of up-reactions were increased 20% whereas down-reactions
were decreased by 20% for toxicity test. We also performed a sensitivity
analysis to test the dependency of the results on the chosen threshold
by simulations between 15%–25%. After linear programming algorithm
was applied to solve the model, the drugs showed inhibitory effect (a
decrease in biomass production N1 × 10−8) on the growth of the cancer
metabolic model were collected as drug candidates for prostate cancer
treatment.
We also evaluated the toxic effects of candidate drugs on healthy
prostate tissue. We used the healthy prostate tissue GEM acquired
from Human Metabolic Atlas (http://www.metabolicatlas.org) [58] to
check drug effects for each biological task using same approach men-
tioned above. We predicted no toxic effect of the drugs in case central
tasks classiﬁed as being involved in energy and redox balancing are
still enabled in the model as previously done in another study [59].
5.6. In vitro cell viability assay
All cells were cultured followed by ATCC instruction. PC3 cells cul-
ture media formulation is F12K Nutrient mix supplemented with 10%
FBS and 1% Penicillin/Streptomycin, RWPE-1 cells was cultured with
Keratinocyte Serum Free Medium (K-SFM) supplemented with Bovine
Pituitary Extract (BPE) andHuman recombinant Epidermal Growth Fac-
tor (EGF) (Kit Catalog Number 17005–042). 22 Rv1, and LNCap cells
were cultured with RPMI 1640 (R2405, Sigma-Aldrich) supplemented
with 10% fetal bovine serum, 1% penicillin and streptomycin. For cell vi-
ability assay, cell lines were seeded to 96 well plate as hextuple, as in
100,000 cells per well. After 24 h of cell seeding, drugs were treated
by media change for two and four days. Cell Counting Kit-8 (Sigma-Al-
drich) was used to measure cell viability as manufacturers' instruction.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ebiom.2019.03.009.
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